WGRX

Wellgistics Health is a sub-scale pharmaceutical wholesaler (Wellgistics LLC serving ~5,000 pharmacies, plus the DelivMeds hub and Wellgistics Pharmacy) that revenue growth cannot rescue. FY2025 revenue of $23.3M grew a healthy-looking +28.7%, but the business sells product below cost: gross profit was NEGATIVE at -$6.43M (gross margin -27.5%), meaning every incremental dollar of sales currently destroys value before a single dollar of overhead. A distributor whose core function is buying and reselling drugs cannot show a negative gross margin and be called a going concern in the normal sense — that is a broken unit economic, and the MD&A itself flags 'margin compression on branded medications,' DIR fees, shift toward lower-margin plans, and reliance on a single primary wholesaler as structural pressures on an already underwater margin.

The balance sheet is effectively insolvent. Stockholders' equity is NEGATIVE -$12.4M (liabilities/equity -3.45x), retained-earnings deficit is -$111M, and cash is a rounding error at $42.6K against $23.5M of total debt ($10.9M current + $12.6M long-term) and $29.8M of current liabilities versus just $2.82M of current assets — a current ratio under 0.1. Operating cash flow was -$10.9M. With essentially no cash, negative working capital, and negative gross margins, the company is wholly dependent on external financing, and it has already been raising it aggressively: shares outstanding doubled (+101.9%) in a single year. The -$101M net loss (a -1,377% swing) reflects this newly combined, integration-heavy entity (Wellgistics LLC + Wood Sage/DelivMeds acquisitions) burning through capital while the risk factors stress 'limited operating history as a combined company' and integration risk.